Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): A review

Multidisciplinary Respiratory Medicine

Volumn 9, Issue 1, 2014, Pages

  D'Amato, Gennaro ^a,b,c   Stanziola, Anna ^d   Sanduzzi, Alessandro ^d   Liccardi, Gennaro ^a   Salzillo, Antonello ^a   Vitale, Carolina ^d   Molino, Antonio ^d   Vatrella, Alessandro ^e   D'Amato, Maria ^d  

^a CARDARELLI HOSPITAL   (Italy)

^b Committee of Ministry of Health on Pollution Climate and Respiratory Health ^*  (Italy)

^c Task Force on Air Pollution Climate Change and Allergic Resp Diseases World Allergy Organization   (Italy)

^d MONALDI HOSPITAL   (Italy)

^e UNIVERSITY OF SALERNO   (Italy)

Author keywords

Allergic asthma; Allergic respiratory diseases; Anti IgE therapy; Monoclonal anti IgE antibody; Omalizumab; Therapy of asthma; Urticaria

Indexed keywords

BECLOMETASONE DIPROPIONATE; FC RECEPTOR; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB; PLACEBO;

AIRWAY REMODELING; ALLERGIC ASTHMA; ANTIGEN BINDING; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFLAMMATORY CELL; INTRINSIC ASTHMA; MULTICENTER STUDY (TOPIC); OCCUPATIONAL ASTHMA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SEVERE PERSISTENT ASTHMA; SINUSITIS;

EID: 84901841540     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/2049-6958-9-23     Document Type: Review

References (61)

1. European Respiratory Society (ERS)/European Lung Foundation: European lung white book. In The first comprehensive survey on respiratory health in Europe. Edited by Loddenkemper R, Gibson GJ, Sibille Y. Sheffield: ERSJ; 2003.
2. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma (GINA) Program: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004, 59:469-478. (Pubitemid 38580764)
3. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, Weiss ST: Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004, 114:40-47. (Pubitemid 39022491)
4. De Marco R, Gappa V, Accordini S, Rava M, Antonicelli L, Bortolami O, Braggion M, Bugiani M, Casali L, Cazzoletti L, Cerveri I, Fois AG, Girardi P, Locatelli F, Marcon A, Marinoni A, Panico MG, Pirina P, Villani S, Zanolin ME, Verlato G, GEIRD Study Group: Trends in the prevalence of asthma and allergic rhinitis in Italy between 1991 and 2010. Eur Respir J 2012, 39 (4):883-892.
5. D'Amato G, Cecchi L, D'Amato M, Liccardi G: Urban air pollution and climate change as environmental risk factors of respiratory allergy: an update. J Invest Allergol Clin Immunol 2010, 20:95-102.
6. Wenzel SE: Asthma: defining of the persistent adult phenotypes. Lancet 2006, 368(9537):804-813.
7. The ENFUMOSA: cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma: European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003, 22:470-477.
8. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, Calhoun WJ, Castro M, Chung KF, Clark MP, Dweik RA, Fitzpatrick AM, Gaston B, Hew M, Hussain I, Jarjour NN, Israel E, Levy BD, Murphy JR, Peters SP, Teague WG, Meyers DA, Busse WW, Wenzel SE, National Heart, Lung, Blood Institute's Severe Asthma Research Program: Characterization of the severe asthma phenotype by the National Heart. Lung and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007, 119:405-413. (Pubitemid 46210080)
9. Busse WW, Banks-Schlegel S, Wenzel SE: Pathophysiology of severe asthma. J Allergy Clin Immunol 2000, 106:1033-1042. (Pubitemid 32006254)
10. Novak N, Bieber T: Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003, 112:252-262. (Pubitemid 36981361)
11. Hollowaj JA, Holgate ST, Semper AE: Expression of the high-affinity IgE receptor on peripheral blood dendritic cells: differential binding of IgE in atopic asthma. J Allergy Clin Immunol 2001, 107:1009-1018. (Pubitemid 32523341)
12. Pelaia G, Vatrella A, Maselli R: The potential of biologics for treatment of asthma. Nat Rev Drug Discov 2012, 11(12):958-972.
13. National Institutes of Health/National Heart Lung and Blood Institute (NHLBI): Global Initiate for Asthma. Bethesda, MD: Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report; 2011.
14. Van Ganse E, Laforest L, Pietri G, Boissel JP, Gormand F, Ben-Joseph R, Ernst P: Persistent asthma: disease control, resource utilisation and direct costs. Eur Respir J 2002, 20:260-270.
15. Boulet L-P, Chapman KR, Cote J, Côté J, Kalra S, Bhagat R, Swystun VA, Laviolette M, Cleland LD, Deschesnes F, Su JQ, DeVault A, Fick RB Jr, Cockcroft DW: Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997, 155:1835-1840. (Pubitemid 27256106)
16. Godard P, Chanez L, Siraudin L, Nicoloyannis N, Duru G: Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002, 19:61-67. (Pubitemid 34105569)
17. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB Jr, Boushey HA: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997, 155:1828-1834. (Pubitemid 27256105)
18. Fahy JV: The anti-IgE treatment strategy for asthma. In New and Exploratory Therapeutic Agents for Asthma: Lung Biology in Health and Disease. Edited by Yeadon M, Diamant Z. New York: Marcel Dekker; 2000:329-342.
19. Chang TW: The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000, 18:157-162.
20. D'Amato G, Oldani V, Donner C: Treating atopic asthma with the anti-IgE monoclonal antibody. Monaldi Arch Chest Dis 2002, 57(2):117-119.
21. D'Amato G: Therapy of allergic bronchial asthma with anti-IgE monoclonal antibody. Expert Opin Biol Ther 2003, 3:371-376.
22. D'Amato G, Bucchioni E, Oldani V, Canonica W: Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab). Treat Respir Med 2006, 5(6):393-398. (Pubitemid 44968299)
23. Takaku Y, Soma T, Nishihara F, Nakagome K, Kobayashi T, Hagiwara K, Kanazawa M, Nagata M: Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma. Int Arch Allergy Immunol 2013, 161(Suppl 2):107-117.
24. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann KC, Rolinck-Werninghaus C, Gräve M, Hultsch T, Wahn U: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002, 109:274-280. (Pubitemid 34158294)
25. Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J: Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001, 17:233-240. (Pubitemid 34150431)
26. D'Amato G: Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of allergic respiratory diseases. Eur J Pharmacol 2006, 533 (1-3):302-307.
27. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001, 18:254-261. (Pubitemid 32776398)
28. Busse W, Coren J, Lanier BQ, McAlary M, Fowler-Taylor A, Della Cioppa G, van As A, Gupta N: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001, 108: 184-190. (Pubitemid 32735398)
29. Babu KS, Polosa R, Morjaria JB: Anti-IgE-emerging opportunities for Omalizumab. Expert Opin Biol Ther 2013, 13(5):765-777.
30. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P: Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001, 108(2):36-45.
31. Buhl R, Soler M, Matz J, Townley R, O'Brien J, Noga O, Champain K, Fox H, Thirlwell J, Della Cioppa G: Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002, 20:73-78. (Pubitemid 34822924)
32. Buhl R, Hanf G, Soler M, Bensch G, Wolfe J, Everhard F, Champain K, Fox H, Thirlwell J: The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002, 20:1088-1094. (Pubitemid 35331863)
33. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H: Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004, 59:701-708. (Pubitemid 38850344)
34. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C: The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005, 115:459-465. (Pubitemid 40341694)
35. Saini SS, MacGlashan DW Jr, Sternisky SA, Togias A, Adelman DC, Lichtenstein LM, Bochner BS: Down-regulation of human basophil IgE and FcεRIα surface densities and mediator release by anti-IgE-infusion reversible in vitro and in vivo. J Immunol 1999, 162:5624-5630. (Pubitemid 29307177)
36. Nopp A, Johansson SGO, Ankerst J, Palmqvist M, Öman H: CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy 2007, 62:1175-1181. (Pubitemid 47374025)
37. Nopp A, Johansson SGO, Adédoyin J, Ankerst J, Palmqvist M, Öman H: After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2009, 65:56-60.
38. Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, Byrne A, Champain K, Thirlwell J, Cioppa GD, Sandström T: Recombinant humanized mAb E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000, 106(2):253-259. (Pubitemid 30644998)
39. Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E, Gustafsson H, Sandström T, Rak S: The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002, 110:68-71. (Pubitemid 36132730)
40. Kopp MV, Brauburger J, Riedinger F, Beischer D, Ihorst G, Kamin W, Zielen S, Bez, Friedrichs F, Von Berg A, Gerhold K, Hamelmann E, Hultsch, Kuehr J: The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 2002, 110:728-735. (Pubitemid 35423175)
41. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K: Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis:SOLAR. Allergy 2004, 59: 709-717. (Pubitemid 38850345)
42. Wenzel S: Severe asthma in adults. Am J Respir Crit Care Med 2005, 172:149-160.
43. Humbert M, Beaskey R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316. (Pubitemid 40293346)
44. Molimard M, de Blay F, Didier A, Le Gros V: Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008, 102(1):71-76. (Pubitemid 350161845)
45. Kopp MV, Hamelmann E, Bendiks M, Zielen S, Kamin W, Bergmann KC, Klein C, Wahn U, DUAL study group: Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol 2013, 24(5):427-433.
46. Hoshino M, Ohtawa J: Effects of adding omalizumab, an anti-immunoglobulin E antibody on airway wall thickening in asthma. Respiration 2012, 83:520-528.
47. Riccio AM, Dal Negro RW, Micheletto C, De Ferrari L, Folli C, Chiappori A, Canonica GW: Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patient. Int J Immunopathol Pharmacol 2012, 25(2):475-484.
48. Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R: Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009, 103(11):1725-1731.
49. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, Lecomte P, Hermans C, MacDonald K, Song M, Abraham I: Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009, 103(11):1633-1642.
50. Niven R: A UK survey of oral corticosteroid use in patients treated with omalizumab. Thorax 2007, 62(Suppl3):A98.
51. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P: Safety and tolerability of omalizumab. Clin Exp Allergy 2009, 39:788-797.
52. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, Kattan M, Teach SJ, Pongracic JA, Chmiel JF, Steinbach SF, Calatroni A, Togias A, Thompson KM, Szefler SJ, Sorkness CA: Randomized trial of Omalizumab (Anti-IgE) for asthma in inner-City children. N Engl J Med 2011, 364:1005-1015.
53. Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J: The eXpeRience registry: the "real-world" effectiveness of omalizumab in allergic asthma. Respir Med 2013, 107(8):1141-1151.
54. Yalcin AD, Cilli A, Bisgin A, Strauss LG, Herth F: Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1bβ levels. Expert Opin Biol Ther 2013, 13(9):1335-1341.
55. Lommatzsch M, Korn S, Buhl R, Virchow JC: Against all odds: anti-IgE for intrinsic asthma? Thorax 2013, doi:10.1136/thoraxjnl-2013-203738.
56. Maselli DJ, Singh H, Diaz J, Peters JI: Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL. Ann Allergy Asthma Immunol 2013, 110(6):457-461.
57. Naclerio RM, Baroody FM, Pinto JM: Should clinicians use omalizumab for the treatment of nasal polyps? J Allergy Clin Immunol 2013, 132(1):247.
58. Tajiri T, Matsumoto H, Hiraumi H, Ikeda H, Morita K, Izuhara K, Ono J, Ohta S, Ito I, Oguma T, Nakaji H, Inoue H, Iwata T, Nagasaki T, Kanemitsu Y, Ito J, Niimi A, Mishima M: Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma. Ann Allergy Asthma Immunol 2013, 110(5):387-388.
59. Vashisht P, Casale T: Omalizumab for the treatment of allergic rhinitis. Expert Opin Biol Ther 2013, 13(6):933-945.
60. Domingo C, Pomares X, Angril N, Rudi N, Amengual MJ, Mirapeix RM: Effectiveness of omalizumab in non allergic severe asthma. J Biol Regul Homeost Agents 2013, 27(1):45-53.
61. Lavaud F, Bonniaud P, Dalphin JC, Leroyer C, Muller D, Tannous R, Mangiapan G, De Blay F: Usefulness of omalizumab in ten patients with severe occupational asthma. Allergy 2013, 68(6):813-815.